Document Detail


Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.
MedLine Citation:
PMID:  19865105     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The role of uric acid (UA) in human physiology is subject to controversy. Either it is an important radical scavenger, a mostly neutral, waste metabolic product that may cause gout and kidney stones if elevated, or it is involved in the causation of hypertension, vascular and renal diseases. Recently we conducted a clinical trial to determine whether raising the serum UA levels through the oral administration of inosine is well tolerated and may benefit patients with multiple sclerosis. An important aspect of the safety profile is whether raising the serum UA levels elevates blood pressure. During the 1-year trial, blood pressure and serum UA levels were monitored in 16 patients. Both parameters were recorded throughout the trial that included 69 visits by patients at baseline and during the placebo phase as well as 138 visits while receiving inosine treatment. We have observed that although the serum UA levels increased significantly during the inosine treatment phase of the trial, from 4.2+/-0.8 to 7.1+/-1.7 mg per 100 ml, blood pressure remained unchanged, averaging 123+/-15/78+/-9. Our findings indicate that raising the serum UA levels to upper normal physiological levels for a period of up to 1-year does not influence blood pressure significantly.
Authors:
S Spitsin; C E Markowitz; V Zimmerman; H Koprowski; D C Hooper
Related Documents :
10872555 - Lipoprotein (a), haemostatic variables and cardiovascular damage in hypertensive patients.
23230005 - Blood pressure-to-height ratio simplifies the diagnosis of hypertension in nigerian chi...
21574875 - Dynamic determination of oxygenation and lung compliance in murine pneumonectomy.
20419975 - Frequency of ischaemic heart disease and stroke in hypertension.
19305185 - Reliability and reproducibility of clinic and home blood pressure measurements in hyper...
656005 - Hypoxia, smoking history, and exercise.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-10-29
Journal Detail:
Title:  Journal of human hypertension     Volume:  24     ISSN:  1476-5527     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-08-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  359-62     Citation Subset:  IM    
Affiliation:
Biotechnology Foundation Laboratories, Thomas Jefferson University, Philadelphia, PA 19107, USA. sspitsin@mail.jci.tju.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Blood Pressure / drug effects*,  physiology
Cross-Over Studies
Double-Blind Method
Female
Humans
Inosine / administration & dosage,  pharmacology*
Male
Middle Aged
Multiple Sclerosis / blood*,  physiopathology*
Treatment Outcome
Uric Acid / blood*
Grant Support
ID/Acronym/Agency:
AT 001301/AT/NCCAM NIH HHS
Chemical
Reg. No./Substance:
58-63-9/Inosine; 69-93-2/Uric Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mapping of Char10, a novel malaria susceptibility locus on mouse chromosome 9.
Next Document:  Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential...